“We are proud to build on our long heritage of developing new insulins with the approval of Lyumjev, an important new treatment option to help control post-meal blood sugar levels,” Leonard Glass, MD, vice president of medical affairs for Lilly, said in a statement. “Keeping blood sugar in the target range following meals can be challenging for people living with diabetes, and the approval of Lyumjev underscores our commitment to meeting their needs.”
“Lilly is committed to ensuring all of our insulins, including Lyumjev, are accessible to people living with diabetes through our wide range of affordability options, such as the Lilly Insulin Value Program,” added Adrienne Brown, vice president of U.S. connected care and insulins for Lilly. “We want people who use Lilly insulin and need help affording their medicine to know that we're here to support them.”
Insulin lispro-aabc was approved in other markets, including Japan and the EU, in March 2020.
"type" - Google News
June 20, 2020 at 04:08AM
https://ift.tt/3fHgIiQ
FDA approves new fast-acting insulin for type 1 and type 2 diabetes - Cardiovascular Business
"type" - Google News
https://ift.tt/2WhN8Zg
https://ift.tt/2YrjQdq
Bagikan Berita Ini
0 Response to "FDA approves new fast-acting insulin for type 1 and type 2 diabetes - Cardiovascular Business"
Post a Comment